Takeda sells generics portfolio to Stada for $660m
06-11-2019
Jonathan Weiss / Shutterstock.com
Takeda has sued Mylan for patent infringement and breach of a licencing agreement over Takeda’s Colcrys (colchicine) drug.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda, Mylan, patent infringement, licencing agreement, Colcrys, colchicine, generics, Food and Drug Administration
